Semaglutide vs Retatrutide: Head-to-Head Data Review

Semaglutide is the incumbent, retatrutide is the challenger, and the gap between them is bigger than most GLP-1 comparisons suggest. This review sets the two molecules side by side on receptor pharmacology, Phase 3 outcomes, tolerability, and regulatory status so readers can see where hype ends and evidence begins.

Key takeaways#

• Semaglutide is a single-target GLP-1 receptor agonist approved for weight management and cardiovascular risk reduction. Retatrutide is an investigational triple agonist hitting GLP-1, GIP and glucagon receptors.
• In its pivotal STEP 1 trial, semaglutide 2.4 mg produced a mean 14.9% weight reduction at 68 weeks versus 2.4% for placebo.
• In the Phase 3 TRIUMPH-1 readout announced in May 2026, retatrutide 12 mg produced a mean 28.3% weight reduction at 80 weeks, with 30.3% at 104 weeks in the BMI ≥35 extension.
• Semaglutide has a completed cardiovascular outcomes trial (SELECT). Retatrutide's cardiovascular outcomes trial (TRIUMPH-3) is expected to read out later in 2026.
• Both molecules share a gastrointestinal-heavy adverse event profile. Retatrutide's higher potency has been associated with a steeper dose-escalation requirement.

The pharmacology gap explains the efficacy gap#

Semaglutide and retatrutide are often lumped into the same "GLP-1 category" in consumer coverage. That framing hides the mechanism.

Semaglutide is a mono-agonist. It binds the GLP-1 receptor, slowing gastric emptying, amplifying glucose-dependent insulin secretion, and reducing appetite via central pathways. That single-target action drives its efficacy ceiling.

Retatrutide is structurally different. It targets glucose-dependent insulinotropic polypeptide receptors, glucagon-like peptide-1 receptors and glucagon receptors. The added glucagon receptor engagement is the mechanistic twist most consumer content misses. Glucagon receptor activity raises energy expenditure and mobilises hepatic lipid stores, which is why the liver-fat data on retatrutide (discussed below) is unusually strong. The paired GIP and GLP-1 action, meanwhile, is what tirzepatide already validated, so retatrutide is best thought of as tirzepatide with an added glucagon arm.

The receptor stack is why the weight-loss numbers diverge. Research suggests the two peptides are not in the same efficacy tier despite the shared "incretin" family label.

Head-to-head weight loss data favours retatrutide by roughly two-fold#

The direct trial comparison is not perfectly matched (different populations, different durations, no head-to-head study yet exists), but the magnitude of the difference is large enough to survive the caveat.

For semaglutide, the reference is STEP 1. Participants who received semaglutide 2.4 mg had a mean change in body weight of −14.9% after 68 weeks compared with −2.4% in the placebo group, and 86% of treated participants attained at least a 5% reduction in total body weight. Follow-on data from the 104-week STEP 5 trial showed the mean weight loss with semaglutide 2.4 mg at weeks 52 and 104 was −15.6% and −15.2% respectively, suggesting minimal weight regain over 104 weeks when treatment is continued.

For retatrutide, the reference is now the Phase 3 TRIUMPH-1 topline. Participants on the 12 mg dose lost an average of 28.3% of their body weight at 80 weeks; those with a starting BMI of 35 or higher who continued on the drug lost up to 30.3% (an average 85.0 lbs) at 104 weeks, and the 4 mg arm hit 19.0% weight loss with a discontinuation rate lower than placebo. That 4 mg number is notable: even the lowest tested dose of retatrutide has been shown to outperform semaglutide's headline STEP 1 result.

The 12mg dose of retatrutide also prompted 45.3% of patients to lose more than 30% of their body weight, an outcome typically associated with weight loss surgery. Preliminary evidence like this positions retatrutide as the first pharmacological candidate to approach bariatric-surgery territory.

Cardiovascular and metabolic outcomes remain semaglutide's strongest card#

Weight loss is a surrogate. Hard cardiovascular endpoints are what regulators and payers eventually anchor to, and semaglutide already has that dossier.

In the SELECT trial, once-weekly semaglutide 2.4 mg was associated with a statistically significant 20% reduction in major adverse cardiovascular events compared with placebo. The full SELECT publication in the New England Journal of Medicine confirmed superiority for the composite of cardiovascular death, nonfatal myocardial infarction and nonfatal stroke at a mean follow-up of 39.8 months. Long-term follow-up analyses have also shown sustained weight loss and additional renal benefit, with studies have shown a 22% lower risk for kidney-related outcomes in the SELECT population.

Retatrutide has no completed cardiovascular outcomes trial yet. TRIUMPH-3, the dedicated cardiovascular-disease trial, is on the 2026 readout schedule but not yet public. So while retatrutide's cardiometabolic biomarker data looks strong, the hard-outcomes evidence base is still asymmetrical in semaglutide's favour.

On liver fat, retatrutide has the more striking preclinical-to-clinical continuum. In a Phase 2a substudy, the mean relative change from baseline in liver fat at 24 weeks was −42.9%, −57.0%, −81.4% and −82.4% for the 1, 4, 8 and 12 mg doses respectively (all P < 0.001 versus placebo), with normal liver fat achieved by 86% of participants on the 12 mg dose. Semaglutide's MASH readouts are also positive but the effect size is smaller.

Tolerability and side effect profiles overlap but not identically#

Both peptides share the gastrointestinal signature that defines the incretin class.

For semaglutide, the STEP 1 safety analysis showed the most common adverse events among subjects treated with semaglutide 2.4 mg were gastrointestinal events, most of which were transient and mild or moderate in severity. In SELECT, adverse events leading to permanent discontinuation of the trial product occurred in 16.6% of the semaglutide group versus 8.2% of placebo, which is the more realistic real-world tolerability signal.

Retatrutide's GI profile is broadly similar in kind but with a steeper dose-titration requirement to keep tolerability acceptable at the 8 mg and 12 mg tiers. The glucagon-receptor arm also introduces two additional watch-items that semaglutide does not have: modest increases in resting heart rate and transient changes in glycaemic control at treatment initiation in some subjects. These have been shown in the Phase 2 dataset and are being tracked closely in the Phase 3 program.

Both molecules carry the class-level boxed warning consideration for medullary thyroid carcinoma based on rodent studies, and both are contraindicated in patients with a personal or family history of MTC or MEN2 syndrome.

Regulatory status defines who can actually access what#

This is the practical answer most readers care about, and it is unambiguous in mid-2026.

Semaglutide 2.4 mg (Wegovy) is approved by the FDA, EMA and Legemiddelverket for chronic weight management, with a full outcomes trial behind it. It is prescribed through licensed clinicians and dispensed through pharmacies.

Retatrutide is investigational. As of early 2026, the regulatory path for retatrutide is becoming clearer but remains subject to trial outcomes. The realistic filing window is late 2026 to early 2027 once the cardiovascular and diabetes readouts are in hand, with potential FDA approval in late 2027. This means anyone comparing the two peptides for a personal decision in 2026 is comparing an approved product to a research-stage compound, not two equal choices. Research-grade retatrutide is available from specialised suppliers for laboratory use only; Klarovel does not sell, stock or fulfill peptides, and any comparison content on the platform is protocol-layer editorial only. See the how it works page for our operating model.

For readers who want to model dosing for either compound in a research context, the peptide calculator tool supports both molecules and applies the same reconstitution logic used in the published trials.

The bottom line: two different tools, not two versions of the same thing#

Semaglutide is the mature, approved, cardiovascular-validated GLP-1 agonist. Retatrutide is the emerging triple agonist with roughly two-fold greater raw weight-loss efficacy and a striking liver-fat signal, but without the hard-outcomes dossier or regulatory approval that semaglutide already carries. The right comparison in 2026 is not "which is better" but "which one has the evidence base that matches the question being asked." For patients, that answer is still semaglutide today. For the research community tracking where obesity pharmacology is heading, retatrutide is the more consequential molecule to watch. Readers who want protocol-layer guidance grounded in primary literature can create a free Klarovel account to access the comparison tooling and structured trial summaries.